Src Family Kinase Inhibition as a Novel Strategy to Augment Melphalan-Based Regional Chemotherapy of Advanced Extremity Melanoma
暂无分享,去创建一个
C. Augustine | D. Tyler | R. Turley | Y. Tokuhisa | G. Beasley | M. Lidsky | Ketan Sharma | T. Ueno | Hiroaki Toshimitsu
[1] K. Grossmann,et al. Molecular testing in malignant melanoma , 2012, Diagnostic cytopathology.
[2] M. Dewhirst,et al. Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma , 2012, Clinical Cancer Research.
[3] V. Sondak,et al. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma , 2011, British Journal of Cancer.
[4] K. Flaherty,et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Montero,et al. Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors , 2011, Clinical Cancer Research.
[6] D. Rimm,et al. In vitro studies of dasatinib, its targets and predictors of sensitivity , 2011, Pigment cell & melanoma research.
[7] S. Woodman,et al. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. , 2010, Biochemical pharmacology.
[8] Sin-Ho Jung,et al. Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy , 2010, Molecular Cancer Therapeutics.
[9] C. Augustine,et al. Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma , 2010, Annals of Surgical Oncology.
[10] E. Haura,et al. Src kinases as therapeutic targets for cancer , 2009, Nature Reviews Clinical Oncology.
[11] G. Mills,et al. Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates , 2009, Molecular Cancer Therapeutics.
[12] Hua Yu,et al. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma , 2009, Melanoma research.
[13] M. Clynes,et al. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines , 2008, Journal of Translational Medicine.
[14] M. Ross,et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma , 2008, British Journal of Cancer.
[15] R. Petersen,et al. Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion , 2008, Annals of Surgical Oncology.
[16] J. Olson,et al. Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma , 2008, Molecular Cancer Therapeutics.
[17] P. Febbo,et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. , 2008, Cancer research.
[18] A. D. Van den Abbeele,et al. Major response to imatinib mesylate in KIT-mutated melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Yan Liu,et al. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. , 2007, Molecular biology of the cell.
[20] C. Augustine,et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents , 2007, Molecular Cancer Therapeutics.
[21] S. Rabbani,et al. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. , 2007, Cancer research.
[22] J. Homsi,et al. The Src signaling pathway: a potential target in melanoma and other malignancies , 2007, Expert opinion on therapeutic targets.
[23] D. Pinkel,et al. Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] K. Brown,et al. A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity , 2006, Annals of Surgical Oncology.
[25] M. Atkins,et al. Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma , 2006, Cancer.
[26] O. Abdel-Wahab,et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine , 2006, Molecular Cancer Therapeutics.
[27] D. Schadendorf,et al. Lack of clinical efficacy of imatinib in metastatic melanoma , 2005, British Journal of Cancer.
[28] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[29] H. Friedman,et al. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. , 2004, American journal of surgery.
[30] J. Parsons,et al. Src family kinases, key regulators of signal transduction , 2004, Oncogene.
[31] N. Carragher,et al. Src-Mediated Phosphorylation of Focal Adhesion Kinase Couples Actin and Adhesion Dynamics to Survival Signaling , 2004, Molecular and Cellular Biology.
[32] J. Kirkwood,et al. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? , 2004, European journal of cancer.
[33] Timothy J. Yeatman,et al. A renaissance for SRC , 2004, Nature Reviews Cancer.
[34] S. Ashley,et al. Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells , 2004, Clinical Cancer Research.
[35] G. Gallick,et al. Src family kinases in tumor progression and metastasis , 2003, Cancer and Metastasis Reviews.
[36] W. Kilarski,et al. Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. , 2003, Experimental cell research.
[37] H. Yoshiji,et al. pp60c-src activation in lung adenocarcinoma. , 2003, European journal of cancer.
[38] C. Szabó,et al. The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors , 2002, Pharmacological Reviews.
[39] M. Frame,et al. Src in cancer: deregulation and consequences for cell behaviour. , 2002, Biochimica et biophysica acta.
[40] P. Kam,et al. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma , 2002, Annals of Surgical Oncology.
[41] L. Tentori,et al. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. , 2002, Pharmacological research.
[42] Heike Allgayer,et al. Activation of Src kinase in primary colorectal carcinoma , 2002, Cancer.
[43] F. Giancotti,et al. A Requirement for Caveolin-1 and Associated Kinase Fyn in Integrin Signaling and Anchorage-Dependent Cell Growth , 1998, Cell.
[44] J. Stockman. KIT as a Therapeutic Target in Metastatic Melanoma , 2013 .
[45] J. Q. Rosso,et al. A Phase 2 Trial of Dasatinib in Advanced Melanoma , 2012 .